|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 31/4402 | |
| A61K 31/42 | |||
| A61P 3/06 | |||
| A61P 25/28 | |||
| A61P 9/00 |
| (11) | Patento numeris | 1465627 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 02805961.6 |
| Europos patento paraiškos padavimo data | 2002-12-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2004-10-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2006-03-08 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2002/040699 |
| Data | 2002-12-18 |
| (87) | Numeris | WO 2003/055485 |
| Data | 2003-07-10 |
| (30) | Numeris | Data | Šalis |
| 345153 P | 2001-12-21 | US |
| (72) |
BROWN, Kathleen, Keating, GlaxoSmithKline, US
BAER, Philip, G., US
|
| (73) |
SMITHKLINE BEECHAM CORPORATION,
One Franklin Plaza, Philadelphia, PA 19101,
US
|
| (54) | DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |
| DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS |